MASI
Price
$136.14
Change
+$0.90 (+0.67%)
Updated
Apr 26, 6:59 PM EST
3 days until earnings call
PACB
Price
$1.47
Change
+$0.09 (+6.52%)
Updated
Apr 26, 6:59 PM EST
5 days until earnings call
Ad is loading...

MASI vs PACB ᐉ Comparison: Which is Better to Invest?

Header iconMASI vs PACB Comparison
Open Charts MASI vs PACBBanner chart's image
Masimo
Price$136.14
Change+$0.90 (+0.67%)
Volume$142.52K
CapitalizationN/A
Pacific Biosciences of California
Price$1.47
Change+$0.09 (+6.52%)
Volume$4.98M
CapitalizationN/A
View a ticker or compare two or three
MASI vs PACB Comparison Chart

Loading...

MASIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PACBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
MASI vs. PACB commentary
Apr 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MASI is a Hold and PACB is a Hold.

COMPARISON
Comparison
Apr 28, 2024
Stock price -- (MASI: $136.14 vs. PACB: $1.47)
Brand notoriety: MASI and PACB are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: MASI: 60% vs. PACB: 78%
Market capitalization -- MASI: $7.66B vs. PACB: $976.68M
MASI [@Medical Specialties] is valued at $7.66B. PACB’s [@Medical Specialties] market capitalization is $976.68M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MASI’s FA Score shows that 1 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).

  • MASI’s FA Score: 1 green, 4 red.
  • PACB’s FA Score: 0 green, 5 red.
According to our system of comparison, MASI is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MASI’s TA Score shows that 4 TA indicator(s) are bullish while PACB’s TA Score has 4 bullish TA indicator(s).

  • MASI’s TA Score: 4 bullish, 5 bearish.
  • PACB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PACB is a better buy in the short-term than MASI.

Price Growth

MASI (@Medical Specialties) experienced а +1.02% price change this week, while PACB (@Medical Specialties) price change was -5.16% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.43%. For the same industry, the average monthly price growth was -5.27%, and the average quarterly price growth was +16.21%.

Reported Earning Dates

MASI is expected to report earnings on Aug 06, 2024.

PACB is expected to report earnings on Jul 31, 2024.

Industries' Descriptions

@Medical Specialties (+0.43% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for MASI with price predictions.
OPEN
A.I.dvisor published
a Summary for PACB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MASI($7.66B) has a higher market cap than PACB($977M). MASI YTD gains are higher at: 16.151 vs. PACB (-85.015). MASI has higher annual earnings (EBITDA): 237M vs. PACB (-277.28M). PACB has more cash in the bank: 631M vs. MASI (163M). PACB (934M) and MASI (970M) have identical debt. MASI has higher revenues than PACB: MASI (2.05B) vs PACB (201M).
MASIPACBMASI / PACB
Capitalization7.66B977M784%
EBITDA237M-277.28M-85%
Gain YTD16.151-85.015-19%
P/E Ratio95.93N/A-
Revenue2.05B201M1,019%
Total Cash163M631M26%
Total Debt970M934M104%
FUNDAMENTALS RATINGS
MASI vs PACB: Fundamental Ratings
MASI
PACB
OUTLOOK RATING
1..100
7111
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
99100
SMR RATING
1..100
8297
PRICE GROWTH RATING
1..100
4798
P/E GROWTH RATING
1..100
3378
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MASI's Valuation (88) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that MASI’s stock grew similarly to PACB’s over the last 12 months.

MASI's Profit vs Risk Rating (99) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that MASI’s stock grew similarly to PACB’s over the last 12 months.

MASI's SMR Rating (82) in the Medical Specialties industry is in the same range as PACB (97) in the Biotechnology industry. This means that MASI’s stock grew similarly to PACB’s over the last 12 months.

MASI's Price Growth Rating (47) in the Medical Specialties industry is somewhat better than the same rating for PACB (98) in the Biotechnology industry. This means that MASI’s stock grew somewhat faster than PACB’s over the last 12 months.

MASI's P/E Growth Rating (33) in the Medical Specialties industry is somewhat better than the same rating for PACB (78) in the Biotechnology industry. This means that MASI’s stock grew somewhat faster than PACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MASIPACB
RSI
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 12 days ago
71%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
64%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
63%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
MASIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PACBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IWY190.473.63
+1.94%
iShares Russell Top 200 Growth ETF
HAUZ20.720.23
+1.12%
Xtrackers International Real Estate ETF
SEPT27.740.22
+0.79%
AllianzIM U.S. Large Cp Buffer10 Sep ETF
MUSI42.580.15
+0.35%
American Century Multisector Income ETF
XHYE38.820.09
+0.24%
BondBloxx US High Yield Energy Sctr ETF